TG Therapeutics (TGTX) Stock News
$TGTX · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on TG Therapeutics (TGTX) in the past 30 days. BORSA’s news read on TGTX is bullish at 65/100, −1 over 24 hours, based on 1 company event over the past 7 days. TGTX last closed at $55.37 on Oct 9, up 1.99% over five sessions and down 0.04% over the past month. TG Therapeutics’ next earnings report is scheduled for Monday, Nov 2.
The wire on $TGTX
newest first · updated · direct subject stories onlyBRIUMVI showed lower risk of 24-week confirmed disability progression and lower annualized relapse rates over five years versus both comparators in an indirect comparison. Findings are exploratory.
bullish 70 · impact 60The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
TG Therapeutics (TGTX) stock: common questions
What is the latest TG Therapeutics stock news?
The highest-impact TGTX story BORSA published in the past 30 days:
· TG Therapeutics publishes five-year comparative analysis of BRIUMVI vs ocrelizumab and ofatumumab in relapsing MS